Interaction between lipoprotein (a) levels and body mass index in first incident acute myocardial infarction

Ruo-Ling Teng 1†, Heng Wang 1†, Bei-Chen Sun 1, Dong-Ping Cai 2 and Yong-Ming He 1*

Abstract

**Background:** Possible interaction between Lipoprotein (a) (Lp(a)) and body mass index (BMI) was investigated with regard to the risk of first incident acute myocardial infarction (AMI).

**Methods:** Cross-sectional study of 1522 cases with initial AMI and 1691 controls without coronary artery disease (CAD) were retrospectively analyzed using logistic regression model. Subjects were categorized based on Lp(a) and BMI and compared with regard to occurrence of AMI by calculating odds ratios (ORs) with 95% confidence intervals (CIs). A potential interaction between Lp(a) and BMI was evaluated by the measures of effect modification on both additive (Relative excess risk due to interaction, RERI) and multiplicative scales.

**Results:** Compared with reference group (BMI < 24 kg/m² and in the first quintile of Lp(a)), multivariable-adjusted analysis revealed that ORs(95%CI) of AMI were 2.27(1.46–3.52) for higher BMI alone; 1.79(1.11–2.90), 1.65(1.05–2.60), 1.96(1.20–3.20) and 2.34(1.47–3.71) for higher Lp(a) alone across its quintiles; and 2.86(1.85–4.40), 3.30(2.14–5.11), 4.43(2.76–7.09) and 5.98(3.72–9.60) for both higher BMI and higher Lp(a), greater than the sum of the both risks each. Prominent interaction was found between Lp(a) and BMI on additive scale (RERI = 2.45 (0.36–4.54) at the fifth quintile of Lp(a)) but not on multiplicative scale.

**Conclusions:** This study demonstrates that BMI and Lp(a) levels are important factors affecting the risk of AMI. Significant interaction is found between Lp(a) and BMI in initial AMI on additive scale, indicating that Lp(a) confers greater risk for initial AMI when BMI is elevated. For those whose BMIs are inadequately controlled, Lp(a) lowering may be an option.

**Trial registration:** This clinical study was not registered in a publicly available registry because this study was a retrospective study first started in 2015. Data are available via the correspondent.

**Keywords:** Interaction, Lipoprotein (a), Body mass index, First incident acute myocardial infarction

---

**Background**

Owing to the known difficulties and enormous health burden of treatment of CAD, better primary prevention through lifestyle modifications is a major public health priority [1]. Increasing evidence supports the hypothesis that Lp(a) and BMI are independent risk factors for CAD [2–8]. The synergistic effects of Lp(a) and BMI may be greater than the sum of their separate effects. Illustration of interaction between them may help provide more effective interventions in susceptible subgroups [9]. However, few studies have explored the interaction between them. The current study performed a cross-sectional study using logistic regression model to...
manifest the interactive effect between Lp(a) and BMI, which may be favourable to reduce the risk of first incident AMI from a new angle [10].

Methods
The database
Case collection and scientific research system for clinical cardiology (CCSSSCC) database has been described elsewhere [11]. The establishment and use of the database were approved by the Institutional Review Boards of the First Affiliated Hospital and the Soochow University (No. 2016SZYYLL00598). All patient records were anonymised and the Institutional Review Board relinquished the need for informed consent before analysis owing to the retrospective nature of data. This study is in accordance with the outlined principles of the Declaration of Helsinki.

Patients
Patient selection has been described elsewhere [11]. In short, this retrospective study included patients hospitalised from January 1, 2010 to December 31, 2013. Exclusion criteria were as follows: 1) patients without Lp(a) examinations; 2) repeat hospitalizations; 3) patients with thyroid dysfunctions; 4) patients with liver and/or kidney dysfunctions; 5) patients with any coexistent entities mentioned above; 6) initial ischemic heart disease; 7) prior CAD; 8) non-CAD patients not confirmed by coronary angiography (CAG). For a patient with multiple hospitalizations, data were collected at the time of first admission. The first laboratory results from multiple laboratory tests performed on hospitalized patients were collected. Information on demographic characteristics, lifestyle, risk factors, laboratory tests, lipid profiles and medications were recorded in detail in our previous studies [11, 12].

Definitions, diagnoses and grouping
Definitions of smoking, drinking status and diagnosis of CAD, initial ischemic heart disease (IHD), prior CAD, primary hypertension (PH), type 2 diabetes mellitus (DM), thyroid dysfunction, liver dysfunction and kidney dysfunction have been described elsewhere in detail [11]. The definition of the first incident AMI was consistent with the third universal MI definition, and there was no clear past history of MI [13]. A total of 1522 first incident AMI cases was diagnosed with chief complaints, cardiac biomarker examinations, electrocardiogram, coronary angiography, echocardiography, and Holter monitoring, respectively or in combination. A total of 1691 non-CAD controls were all confirmed by normal coronary angiograms. BMI was calculated as weight in kilograms divided by height in meters squared, with a BMI < 24 kg/m² was regarded as normal in this study [14].

Patients were categorized on the basis of Lp(a) and BMI. We categorized all subjects into quintiles (Q1 ≤ 34 mg/l, Q2 ≤ 65 mg/l, Q3 ≤ 118 mg/l, Q4 ≤ 246.9 mg/l and Q5 ≤ 2138 mg/l) on the basis of the serum level of Lp(a), and dichotomized all subjects at a cutoff of 24 kg/m² of BMI [15]. Risk of AMI was assessed based on four groups: 1) Reference group: patients within Q1 of Lp(a) and BMI < 24 kg/m²; 2) Group with higher Lp(a) alone: patients within Q2-Q5 of Lp(a) and BMI < 24 kg/m²; 3) Group with higher BMI alone: patients within Q1 of Lp(a) and BMI ≥ 24 kg/m²; 4) Group with both higher Lp(a) and higher BMI: patients within Q2-Q5 of Lp(a) and BMI ≥ 24 kg/m².

Lab measurements
Lab measurements have been described elsewhere [11]. Blood samples were taken after eight hours of fasting on the second day morning of admission. The latex-enhanced immunoturbidimetric diagnostic reagent kits from Sekisui Diagnostic Ltd. have been used to quantify the Lp(a) concentrations and they are insensitive to the isoforms of Lp(a). The assay range is 10–1000 mg/l. To ensure the Lp(a) concentrations were within the security range of the assay and would not mistakenly be considered as a low concentration due to antigen excess, the blood samples with the Lp(a) > 1000 mg/l were routinely diluted 1:4. Lp(a) protein calibrator provided by Sekisui Co. Ltd., in accordance with the IFCC PRM-2, has been used to calibrate the Lp(a) examination results [11]. Other biochemical indexes and lipid profiles were quantitatively determined according to the manufacturer’s instructions. The intra-assay and inter-assay CVs were 2.5 and 3.11%, respectively.

Statistical methods
All continuous variables involved in this study did not conform to the normal distribution and were represented by median (inter quartile range, IQR). Rank-sum test was used for group comparison. Categorical variables were represented by frequency and percentage and the chi-square test was used for group comparison. Lp(a) levels were divided into quintiles and the first quintile was used as a reference. Unconditional logistic regression was adopted for model fitting. Crude ORs and adjusted ORs (with the adjustment of eleven factors including age, sex, smoking status, drinking status, diabetes mellitus (DM), primary hypertension (PH), high-density lipoprotein cholesterol (HDL), triglycerides (TG), albumin (Alb), serum creatinine (Cr) and low-density lipoprotein-cholesterol (LDL-C)) were reported. The results were presented in the way recommended by International Journal of Epidemiology [10]. Relative excess risk due to interaction (RERI) was used to evaluate additive interaction, which was calculated for binary variables
Multiplicative interaction was assessed using the ratio of IRRs: $\text{IRR}_{11}/(\text{IRR}_{10} \times \text{IRR}_{01})$ \cite{9}. If 95% CI of RERI does not contain 0, then there is additive interaction; if $P$ value of product term in logistic model is $< 0.05$, then there is multiplication interaction \cite{17–19}. Statistical analyses and graphics were performed using STATA 15.0. Two-tailed $P<0.05$ was considered to be statistically significant.

**Results**

As described in detail elsewhere \cite{11}, a total of 13,834 person-time hospitalized patients were retrospectively included for analysis, among whom, 10,621 were excluded based on the exclusion criteria. As a result, a total of 3213 patients with 1522 cases with initial AMI and 1691 controls without CAD confirmed by coronary angiography met for final analysis. Details were shown in Fig. 1. Baseline characteristics for initial AMI group and non-CAD group were given particularly in Table 1 reprinted from references \cite{12}.

**Odds ratios of first incident AMI in higher BMI alone**

Compared with the reference group, OR (95%CI) of first incident AMI was 1.90(1.34–2.69) for higher BMI alone, while after multivariable adjustments, OR (95%CI) was strengthened to 2.27(1.46–3.52). Details were seen in Table 2.

**Odds ratios of first incident AMI in higher Lp(a) alone**

Compared with the reference group, ORs(95%CI) for first incident AMI were 2.77(1.95–3.94), 3.25(2.29–4.62), 4.46(3.13–6.37), 5.42(3.77–7.79) and multivariable-adjusted ORs (95%CI) were 2.86(1.85–4.40), 3.30(2.14–5.11), 4.43(2.76–7.09), 5.98(3.72–9.60), respectively, across the Lp(a) quintiles. The risk of AMI accelerated remarkably from Q3 to Q5 in this group. Details were seen in Table 2.

**Interactive effects of both higher BMI and higher Lp(a) levels on the risk of first incident AMI**

The RERI was 1.39 (0.26–2.52) in Q4 and 1.62 (0.21–3.03) in Q5 before adjustment. After multivariable adjustment, the RERI was 2.45 (0.36–4.54) in Q5, and its 95% CIs did not include 0, meaning that the estimated joint effect on the additive scale of Lp(a) and BMI together was greater than the sum of the estimated effects of Lp(a) and BMI alone. Therefore, there was a positive interaction on the additive scale. However, the $P$ value...
Table 1 Baseline characteristics

| Characteristics                  | Total       | Initial AMI | Non-CAD     | P value |
|----------------------------------|-------------|-------------|-------------|---------|
| **N**                            | 3213        | 1522        | 1691        |         |
| **Demographic data**             |             |             |             |         |
| Age (IQR), year                  | 63 (15)     | 64 (18)     | 62 (13)     | < 0.001 |
| Male n (%)                       | 2117 (65.9) | 1229 (80.8) | 888 (52.5)  | < 0.001 |
| Height (IQR), cm                 | 165 (10)    | 165 (9)     | 163 (12)    | < 0.001 |
| Weight (IQR), kg                 | 65 (11)     | 65 (7)      | 65 (14)     | 0.693   |
| BMI (IQR)                        | 24.1 (3.0)  | 24.1 (1.4)  | 24.4 (4.0)  | < 0.001 |
| **Marriage n (%)**               |             |             |             | 0.019   |
| Divorced                         | 3 (0.1)     | 3 (0.2)     | 0 (0.0)     |         |
| Married                          | 3168 (98.6) | 1492 (98.0) | 1676 (99.1) |         |
| Unmarried                        | 25 (0.8)    | 15 (1.0)    | 10 (0.6)    |         |
| Widowed                          | 17 (0.5)    | 12 (0.8)    | 5 (0.3)     |         |
| **Life styles**                  |             |             |             |         |
| Smoking status n (%)             |             |             |             | < 0.001 |
| Never                            | 1681 (52.3) | 578 (38.0)  | 1103 (65.2) |         |
| Past smoking                     | 276 (8.6)   | 123 (8.1)   | 153 (9.1)   |         |
| Current smoking                  | 1256 (39.1) | 821 (53.9)  | 435 (25.7)  |         |
| **Drinking status n (%)**        |             |             |             | < 0.001 |
| Never                            | 2488 (77.4) | 1108 (72.8) | 1380 (81.6) |         |
| Past drinking                    | 73 (2.3)    | 35 (2.3)    | 38 (2.3)    |         |
| Current drinking                 | 652 (20.3)  | 379 (24.9)  | 273 (16.1)  |         |
| **Past history n (%)**           |             |             |             |         |
| PH                               | 2029 (63.2) | 926 (60.8)  | 1103 (65.2) | 0.010   |
| DM                               | 616 (19.2)  | 346 (22.7)  | 270 (16.0)  | < 0.001 |
| **Blood analysis**               |             |             |             |         |
| Total protein (IQR), g/l         | 66.4 (8.1)  | 64.8 (7.7)  | 67.4 (7.7)  | < 0.001 |
| Albumin (IQR), g/l               | 41.1 (5.5)  | 39.5 (5.8)  | 42.1 (4.9)  | < 0.001 |
| Creatinine (IQR), μmol/l         | 74.0 (24.0) | 78.0 (24.1) | 72.0 (23.0) | < 0.001 |
| ALT (IQR), u/l                   | 26.0 (29.0) | 40.2 (39.8) | 19.0 (13.0) | < 0.001 |
| AST (IQR), u/l                   | 30.0 (97.0) | 123.5 (245.0) | 22.0 (8.0) | < 0.001 |
| Hemoglobin (IQR), g/l            | 135.0 (19.0) | 135.0 (20.0) | 134.0 (19.0) | 0.375   |
| **Lipid profiles**               |             |             |             |         |
| TC, mmol/l                       | 4.1 (1.3)   | 4.1 (1.3)   | 4.0 (1.2)   | < 0.001 |
| TG, mmol/l                       | 1.3 (1.0)   | 1.2 (1.0)   | 1.3 (1.0)   | 0.009   |
| Lp(a), mg/l                      | 88 (158)    | 111 (192)   | 71 (126)    | < 0.001 |
| Apo A, g/l                       | 1.3 (0.2)   | 1.2 (0.2)   | 1.3 (0.2)   | < 0.001 |
| Apo B, g/l                       | 0.9 (0.3)   | 0.9 (0.3)   | 0.9 (0.3)   | < 0.001 |
| HDL-C, mmol/l                    | 1.1 (0.3)   | 1.0 (0.3)   | 1.1 (0.3)   | < 0.001 |
| LDL-C, mmol/l                    | 2.5 (1.0)   | 2.6 (1.1)   | 2.4 (0.9)   | 0.038   |
| **Medications n (%)**            |             |             |             | 0.001   |
| Rosuvastatin                     | 326 (15.7)  | 223 (15.9)  | 103 (15.5)  |         |
| Fluvastatin                      | 11 (0.5)    | 3 (0.2)     | 8 (1.2)     |         |
| Atorvastatin                     | 897 (43.3)  | 638 (45.4)  | 259 (39.0)  |         |
| Simvastatin                      | 837 (40.4)  | 542 (38.6)  | 295 (44.4)  |         |
Table 1 Baseline characteristics (Continued)

| Characteristics | Total | Initial AMI | Non-CAD | P value |
|-----------------|-------|-------------|---------|---------|
| N               | 3213  | 1522        | 1691    |         |
| Imaging         | 3076  | 1385        | 1691    | <0.001  |
| CAG n (%)       | 95.7  | 91.0        | 100.0   |         |

Note: Continuous variables were expressed as median (inter quartile range; IQR); categorical variables were expressed as percentage. Abbreviations: N number; CAD coronary artery disease; Initial AMI initial acute myocardial infarction; BMI body mass index; PH primary hypertension; DM diabetes mellitus; ALT alanine aminotransferase; AST aspartate aminotransferase; TC total cholesterol; TG triglyceride; Lp(a), lipoprotein(a); Apo A apolipoprotein A1; Apo B apolipoprotein B; HDL-C high density lipoprotein cholesterol; LDL-C low density lipoprotein cholesterol; CAG coronary angiogram.

of product term of BMI and Lp(a) was >0.05, indicating that the interaction on the multiplicative scale was negative. Details were seen in Table 3.

Discussion

In this large cross-sectional study, we have found that BMI and Lp(a) are independently relevant to a high risk of the first incident AMI after adjusting for baseline characteristics, lifestyles and laboratory exams. A combination of high BMI and high Lp(a) is in connection with the highest risk of initial AMI. Significant interaction is found between Lp(a) and BMI in initial AMI on additive scale, but not on multiplicative scale (P > 0.05).

BMI and the first incident AMI

In the current study, a higher BMI was associated with a 2.27-fold increased risk of the first incident AMI, consistent with previous studies [20–22]. Therefore, measures taken against adult obesity may be a preventive strategy against AMI.

Interaction between BMI and Lp(a) on first incident AMI

According to our study, a combination of high BMI and high Lp(a) was related to the highest risk of first incident AMI.

Table 2 Odds ratios of first incident AMI for elevated Lp(a) and BMI

| Lp(a) | BMI ≤ 24 | BMI ≥ 24 |
|-------|----------|----------|
|       | Crude *OR (95% CI) | Crude *OR (95% CI) | Crude *OR (95% CI) | *OR (95% CI) |
| Q1    | 177/61  | 1.0      | 254/166  | 1.90 (1.34–2.69) | 2.27 (1.46–3.52) |
| Q2    | 150/82  | 1.59 (1.07–2.36) | 204/195  | 2.77 (1.95–3.94) | 2.86 (1.85–4.40) |
| Q3    | 161/90  | 1.79 (1.11–2.90) | 189/212  | 3.25 (2.29–4.62) | 3.30 (2.14–5.11) |
| Q4    | 137/103 | 2.18 (1.48–3.21) | 154/237  | 4.46 (3.13–6.37) | 4.43 (2.76–7.09) |
| Q5    | 137/137 | 2.90 (1.99–4.22) | 128/239  | 5.42 (3.77–7.79) | 5.98 (3.72–9.60) |

*OR (95% CI) for higher Lp(a) within strata of BMI:

- Q1: 1.79 (1.11–2.90)
- Q2: 1.65 (1.05–2.60)
- Q3: 1.96 (1.20–3.20)
- Q4: 2.34 (1.47–3.71)
- Q5: 2.90 (1.99–4.22)

Note: Q1-Q5: quintile of Lp(a); Q1: ≤34 mg/L; Q2: 65–86 mg/L; Q3: 118–211 mg/L; Q4: 246.9–255 mg/L; Q5: ≥211 mg/L. a, comparing with BMI < 24 kg/m2 and Lp(a) ≤ 34 mg/L; b, OR of BMI ≥ 24 kg/m2 comparing with BMI < 24 kg/m2 in the same Lp(a) level; c, OR of Lp(a) in Q2–Q5 comparing with Q1 in the same BMI level. Adjustment: age, sex, smoking, drinking, diabetes mellitus, primary hypertension, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride, albumin, creatinine. Abbreviations: Lp(a) lipoprotein(a); BMI body mass index; AMI acute myocardial infarction; OR odds ratio; CI confidence interval; ca/co cases/controls.
AMI. Significant interaction was found between Lp(a) and BMI in initial AMI on additive scale (RERI 2.45(0.36–4.54) in Q5), which means the synergy of Lp(a) and BMI was greater than the sum of their respective effects [9]. Some authors have emphasized statistical interaction in the additive model as the basis for assessing biological interaction especially when the additive and multiplicative interactions are in opposite directions [16, 18, 25]. Therefore, a positive additive interaction seems more plausible than a negative multiplicative interaction and deserves more attention. It is well known that acute coronary events are caused by the rupture of atherosclerotic plaques and the blockage of lumen by thrombosis. Lp(a) can inhibit the formation of active plasmin due to its homology with plasminogen [23]. Coincidentally, obesity is related to increased plasminogen activator inhibitor-1 (PAI-1) [21]. Secondly, Lp(a) has been proved to have an impact on platelet activation or aggregation caused by various agonists [23]. Obesity is also associated with increased platelet activation [26]. Moreover, obesity and high levels of Lp(a) are interacting on mediating inflammatory responses. All signs indicate that the co-existence of high levels of Lp(a) and high BMI may have a synergistic effect on plaque rupture and thrombosis. This interaction between BMI and Lp(a) may modify risk of the AMI. If these associations are causal, our findings suggest that interventions to prevent AMI include not only weight control but also Lp(a) lowering.

**Strengths and limitations**

This study has the following advantages and disadvantages. To our knowledge, this study is the first to explore additive and multiplicative interactions between Lp(a) and BMI on risk of AMI. Non-CAD controls were identified by coronary angiography, which was a gold standard for the diagnosis of CAD, enabling us to group individuals more accurately. However, Salim Yusuf found that waist-to-hip ratio would be a stronger indicator of myocardial infarction than BMI [27]. Unfortunately, we lacked the data of waist and hip circumference, as well as information on dietary factors that may possibly modify associations between serum lipid and BMI. In addition, the cross-sectional study design is inevitably open to confounders which may exaggerate or diminish the association between exposure and major outcomes. Thus we incorporated possible risk factors into the logistic model fitting to minimize the impact.

**Conclusions**

This study demonstrates that BMI and Lp(a) levels are important factors affecting the risk of AMI. Significant interaction is found between Lp(a) and BMI in initial AMI on additive scale in Chinese Han population, indicating that Lp(a) confers greater risk for initial AMI when BMI is elevated. For those whose BMIs are inadequately controlled, Lp(a) lowering may be an option.

**Abbreviations**

Lp(a): Lipoprotein(a); BMI: Body mass index; AMI: Acute myocardial infarction; CAD: Coronary artery disease; RERI: Relative excess risk due to interaction; OR: Odds ratio; CI: Confidence interval; CCSSCSC: Case collection and scientific research system for clinical cardiology; CAG: Coronary angiography; IHD: Ischemic heart disease; PH: Primary hypertension; DM: Diabetes mellitus; IQR: Inter quartile range; HDL-C: High-density lipoprotein cholesterol; TG: Triglycerides; Alb: Albumin; Cr: Creatinine; LDL-C: Low-density lipoprotein-cholesterol; SNPs: Single nucleotide polymorphisms

**Acknowledgements**

None.

**Authors’ contributions**

Teng RL and He YM wrote the main manuscript text and designed the current study; Teng RL and Wang H analyzed the data and created the tables; Sun BC and Cai DF participated in clinical data collection. All the authors were involved in the draft; revision and approval of the final version.

**Funding**

This work was in part supported by the Sci-Tech Development Program of Suzhou City (SYS2019040 to He YM). This funding had no impacts on the conclusions in this study.

**Availability of data and materials**

The data that support the findings of this study are available from the First Affiliated Hospital of Soochow University, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the First Affiliated Hospital of Soochow University.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
